AbbVie's 2024 Revenue Grows Despite Humira Decline, Skyrizi and Rinvoq Surge
Company

AbbVie’s 2024 Revenue Grows Despite Humira Decline, Skyrizi and Rinvoq Surge

PegBio's Lead Product PB-119 Clears HKEX Hearing for Type 2 Diabetes and Obesity Treatment
Company

PegBio’s Lead Product PB-119 Clears HKEX Hearing for Type 2 Diabetes and Obesity Treatment

Roche Reports 7% Revenue Growth in 2024, Driven by Oncology and Ophthalmology
Company

Roche Reports 7% Revenue Growth in 2024, Driven by Oncology and Ophthalmology

DeepSeek Enhances Biopharma IND and NDA Processes with AI
CompanyDigital

DeepSeek Enhances Biopharma IND and NDA Processes with AI

Enhertu Approved by FDA for HR-Positive, HER2-Low Breast Cancer
CompanyDrug

Enhertu Approved by FDA for HR-Positive, HER2-Low Breast Cancer

Suzhou Vigonvita Life Sciences Files for HKEX IPO
Company

Vigonvita Life Sciences Targets HKEX IPO with Integrated Biopharma Model

CompanyDeals

CStone Pharmaceuticals Partners with SteinCares for Sugemalimab Commercialization in Latin America

MicroPort's Fireliums Receives NMPA Approval for Coronary Bifurcation Stenosis Treatment
CompanyMedical Device

MicroPort’s Fireliums Receives NMPA Approval for Coronary Bifurcation Stenosis Treatment

MicroPort's TomaHawk Intravascular Shock Wave Therapy Device Approved by NMPA
CompanyMedical Device

MicroPort’s TomaHawk Intravascular Shock Wave Therapy Device Approved by NMPA

FDA Clears sBLA for Eisai and Biogen's Leqembi Maintenance Dosing
CompanyDrug

FDA Clears sBLA for Eisai and Biogen’s Leqembi Maintenance Dosing

Jiangsu Yuyue Partners with Inogen for International Distribution and R&D
CompanyDeals

Jiangsu Yuyue Partners with Inogen for International Distribution and R&D

Guangzhou Innogen's Efsubaglutide Alfa Approved by NMPA for Type 2 Diabetes
CompanyDrug

Guangzhou Innogen’s Efsubaglutide Alfa Approved by NMPA for Type 2 Diabetes